Document resource
Tuberculosis (TB) remains a global public health threat, occurring in more than 10 million people and killing over 1.2 million humans each year.1 The world ushered in a new era for TB care and prevention in 2015 when the end TB strategy, with its ambitious goal of ending TB as a global public health threat by 2035, was adopted by the World Health Assembly. While progress is being made, the pace of change in the burden of TB is unfortunately too slow and it is doubtful that the end of TB will be reached by 2035.2 In 2023, after the devastating shocks of the COVID-19 pandemic on TB care and prevention, there was a rekindling of the rays of hope: TB notifications increased to the highest level ever observed, reducing the number of missing people with TB. At the global level, the proportion of people with new and relapse TB who are successfully treated reached 88% in 2022.1 This should be a reason for celebration; however, TB treatment success rate alone is not a holistic way of gauging how well TB care and prevention programmes are influencing the lives of people experiencing TB disease. This indicator ignores the proportion of people who, despite successfully completing treatment for TB, develop post-TB lung disease (PTLD) and continue to experience symptoms, have persistent radiological abnormalities on lung imaging and/or have lung function abnormalities and physical disability following the TB episode.